Nautilus Biotechnology (NAUT) Net Income towards Common Stockholders (2020 - 2021)
Nautilus Biotechnology (NAUT) reported Net Income towards Common Stockholders of -$2.1 million for Q1 2021, down 51.16% sequentially from -$1.4 million in Q4 2020.
Nautilus Biotechnology (NAUT) Net Income towards Common Stockholders (2020 - 2021) Analysis & Trends
Nautilus Biotechnology (NAUT) has 2 years of Net Income towards Common Stockholders data on file, last reported at -$2.1 million in Q1 2021.
- For the quarter ending Q1 2021, Net Income towards Common Stockholders changed N/A year-over-year to -$2.1 million; the trailing twelve-month figure through Dec 2021 stood at -$2.1 million (changed N/A YoY), and the FY2020 full-year result was -$41.3 million, changed N/A from the prior year.
- Net Income towards Common Stockholders slipped to -$2.1 million in Q1 2021, from -$1.4 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$586388.0 in Q3 2020 to a low of -$2.1 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Nautilus Biotechnology | 212.11 Mn | 116.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | -2.08 Mn |
| Dec 31, 2020 | -1.38 Mn |
| Sep 30, 2020 | -586,388.00 |